PCRX

Pacira Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000

$36.39Close $1.5BMarket cap $19.16 – $36.4252-week range Nov 5, 2026Next report · before the open

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 94 · stronger than 94% of stocks over 12 months
RS line at a 1-year high outperforming the S&P 500 more than at any point this year
Near its high at its 52-week high
Volume drying up last 10 days 38% under the 50-day average
Accumulation up-day volume 2.4× down-day volume over 50 sessions

Cautions

Extended 17.1 ATR above its 50-day average
Results soon Nov 5, 2026, in 4 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 4, 2026

Off 12-month high 0%

1wk 0.1% price change

1mo 45.3% price change

12-month return 71% market up 11% · its own up 62%

F-score 9 / 9 Exceptional

Altman Z 2.38 Moderate risk

P/E 213.7× price / earnings

PEG — P/E / EPS growth

P/B 2.2× price / book

Earnings yield 1.1% EBIT / enterprise value

Cheaper than 62% of the market · cheap

Revenue growth 4% year on year

EPS growth — latest quarter

Sales growth 6% latest quarter · +1 pts

ROE 1% return on equity

Free cash margin 19% $136.7M FCF

D/E 0.54 long-term debt / equity

Net debt / EBITDA 1.9×

Interest cover 1.1×EBIT / interest

Piotroski tests

profitable on its assets
generating cash from operations
profitability improving
profits backed by cash
reduced long-term debt
short-term liquidity improved
no new shares issued
gross margin widened
assets working harder

Repair signals

Gross margin 75.7% → 79.4%

Trade setup

ATR% 1.5% $0.54 a day · 2×ATR $35.32

RS 94 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.5× vs 50-day average

Up/down volume 2.42 50 sessions

Implied move — no option chain · report Nov 5, 2026

Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Interest is covered, but thinly Earnings before interest cover the interest bill 1.1 times, leaving little room if profits fall.

Last reported Aug 4, 2026

Results reaction Aug 4, 2026-9% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $726.4M +4% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $7.0M back to a profit

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $136.7M -24% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 79%
Net 1%
Free cash 19%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $213.6M net debt

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 41.12m -5.8% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$429.6M	$541.5M	$666.8M	$675.0M	$701.0M	$726.4M
Gross margin	73%	74%	70%	73%	76%	79%
Operating income	$46.4M	$89.9M	$60.0M	$87.7M	-$73.4M	$19.2M
Net income	$145.5M	$42.0M	$15.9M	$42.0M	-$99.6M	$7.0M
Net margin	34%	8%	2%	6%	-14%	1%
Earnings per share	$3.33	$0.92	$0.34	$0.81	-$2.15	$0.16
Free cash flow	$39.2M	$79.9M	$115.2M	$139.5M	$178.8M	$136.7M
Free cash margin	9%	15%	17%	21%	26%	19%
Cash	$100.0M	$585.6M	$104.1M	$153.3M	$276.8M	$158.5M
Long-term debt	—	—	$689.5M	$522.4M	$383.5M	$372.2M
Shareholders' equity	$619.7M	$730.4M	$775.0M	$870.1M	$778.3M	$693.1M
Shares outstanding	43.64m	44.73m	45.93m	46.48m	46.24m	41.12m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 4, 2026	Quarterly ↗	Jun 30, 2026	35d
Apr 30, 2026	Quarterly ↗	Mar 31, 2026	30d
Feb 26, 2026	Annual ↗	Dec 31, 2025	57d
Nov 6, 2025	Quarterly ↗	Sep 30, 2025	37d
Aug 5, 2025	Quarterly ↗	Jun 30, 2025	36d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Feb 27, 2025	Annual ↗	Dec 31, 2024	58d
Nov 6, 2024	Quarterly ↗	Sep 30, 2024	37d
Jul 30, 2024	Quarterly ↗	Jun 30, 2024	30d
May 7, 2024	Quarterly ↗	Mar 31, 2024	37d
Feb 29, 2024	Annual ↗	Dec 31, 2023	60d
Nov 2, 2023	Quarterly ↗	Sep 30, 2023	33d

Current reports

Filed	Disclosed
Oct 8, 2026	Material agreement · Regulation FD ↗
Aug 4, 2026	Results ↗
Jun 30, 2026	Material agreement · Regulation FD ↗
Jun 11, 2026	Director or officer change · Shareholder vote · Other events ↗
Apr 30, 2026	Results ↗
Feb 26, 2026	Results ↗
Jan 28, 2026	Director or officer change · Regulation FD ↗
Jan 8, 2026	Results ↗
Nov 6, 2025	Results ↗
Aug 5, 2025	Results ↗
Jul 10, 2025	Restructuring · Regulation FD ↗
Jul 7, 2025	Material agreement · Agreement ended · New obligation ↗